Time-in-range derived from self-measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: a participant-level pooled analysis of three phase 3 LixiLan randomized controlled trials
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F24%3A00085066" target="_blank" >RIV/00023001:_____/24:00085066 - isvavai.cz</a>
Result on the web
<a href="https://dom-pubs.pericles-prod.literatumonline.com/doi/epdf/10.1111/dom.15811" target="_blank" >https://dom-pubs.pericles-prod.literatumonline.com/doi/epdf/10.1111/dom.15811</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/dom.15811" target="_blank" >10.1111/dom.15811</a>
Alternative languages
Result language
angličtina
Original language name
Time-in-range derived from self-measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: a participant-level pooled analysis of three phase 3 LixiLan randomized controlled trials
Original language description
AimTo evaluate the efficacy of a fixed-ratio combination of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) in people with type 2 diabetes (T2D) using derived time-in-range (dTIR). MethodsParticipant-level data from LixiLan-L, LixiLan-O and LixiLan-G were pooled and dTIR (70-180 mg/dL), derived time-above-range (> 180 mg/dL) and derived time-below-range (dTBR; < 70 mg/dL) were calculated from participant seven-point self-monitored blood glucose profiles. ResultsThis pooled analysis included data from 2420 participants receiving iGlarLixi (n = 1093), iGlar (n = 836), Lixi (n = 234) or a glucagon-like peptide-1 receptor agonist (GLP-1 RA) (n = 257). Numerically greater improvements in least square (LS) means dTIR were seen from baseline to end of treatment (EOT) with iGlarLixi (25.7%) versus iGlar (15.8%), Lixi (11.7%) or GLP-1 RA (16.2%). At EOT, the mean (standard deviation) dTBR was 0.71% +/- 3.4%, 0.61% +/- 3.2%, 0.08% +/- 1.0% and 0.0% +/- 0.0% for iGlarLixi, iGlar, Lixi and GLP-1 RA, respectively. In a subgroup analysis, participants aged younger than 65 years (n = 1690) and 65 years or older (n = 713) showed numerically greater improvements in LS means dTIR from baseline to EOT with iGlarLixi versus iGlar, Lixi or GLP-1 RA. ConclusionsiGlarLixi achieved improvements in dTIR, with low dTBR values, providing further evidence to inform clinical outcomes with the use of iGlarLixi.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30202 - Endocrinology and metabolism (including diabetes, hormones)
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Diabetes, obesity and metabolism
ISSN
1462-8902
e-ISSN
1463-1326
Volume of the periodical
26
Issue of the periodical within the volume
11
Country of publishing house
GB - UNITED KINGDOM
Number of pages
10
Pages from-to
5046-5055
UT code for WoS article
001308397300001
EID of the result in the Scopus database
2-s2.0-85203326956